In WM852 melanoma–lymphatic endothelial co-cultures, 50 µM NSC 405020 for 48 h reduced the actin-normalized combined Notch3/NICD3 immunoblot signal relative to DMSO-treated co-cultures. This result supports a cellular pathway response in that model. [2]
Isolated MT1-MMP catalytic-domain assay
Biochemical assay · Purified MT1-MMP catalytic domain (CAT), fluorescent peptide cleavage [1]
The reported IC50 exceeds 100 µM for catalytic-domain inhibition; this is a lower bound in a catalytic assay, not potency for PEX-dependent cellular effects.
Literature-Reported Treatment Conditions
- Method
- Concentration-dependent fluorescent peptide cleavage assay
- Reported limits
- The complete concentration series and matched vehicle details are not specified in the selected assay description; the figure reports the IC50 bound.
Methods and source locations
Compound reported in the paper: NSC 405020; Compound label in the paper: Compound 9 (NSC405020)
Evidence concerns the reported NSC405020 material; it does not establish stereoisomer-specific activity or validate a current Adooq lot.
Figure 4, compound 9; Methods: Cleavage of fluorescent peptide; Compound databases
Inhibition of fluorescent peptide cleavage by MT1-MMP CAT: 10 nM CAT and 10 µM fluorescent peptide substrate; 30 min compound preincubation at ambient temperature, activity measured at 37°C; triplicate assay. — Figure 4, compound 9; Methods: Cleavage of fluorescent peptide
Cellular MT1-MMP homodimerization
Cell-based study · MCF7-MT-V5 cells expressing MT1-MMP-FLAG; untagged MCF7-MT cells as control [1]
NSC405020 reduced co-precipitated MT1-MMP-V5 in the FLAG pull-down assay, consistent with interference in MT1-MMP homodimerization.
Literature-Reported Treatment Conditions
- Treatment concentration
- 100 µM
- Exposure duration
- 24 h compound exposure, beginning 24 h after transfection
- Method
- Cell treatment followed by co-immunoprecipitation and western blot
- Vehicle
- DMSO; concentration not specified for this experiment
- Reported limits
- No numerical dimerization effect size, binding constant or replicate count is stated for this blot.
Methods and source locations
Compound reported in the paper: NSC 405020; Compound label in the paper: Compound 9 (NSC405020)
Evidence concerns the reported NSC405020 material; it does not establish stereoisomer-specific activity or validate a current Adooq lot.
Figure 5F; Results: Compound 9 affects the PEX function; Methods: Cells and Compound databases
MT1-MMP-V5 recovered in anti-FLAG precipitates: Anti-FLAG pull-down followed by anti-V5 western blot; DMSO comparison, untagged MT1-MMP control and actin loading control. — Figure 5F and caption; Results: Compound 9 affects the PEX function
Notch3 response in melanoma–lymphatic endothelial co-culture
Cell-based study · Human WM852 melanoma cells co-cultured with primary lymphatic endothelial cells (LECs), followed by magnetic separation [2]
NSC405020 decreased the actin-normalized combined full-length Notch3 and NICD3 band signal in LEC-co-cultured WM852 cells compared with the DMSO co-culture control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 µM
- Exposure duration
- 48 h during 2D LEC–WM852 co-culture
- Method
- Addition to growth medium during co-culture, then separation and immunoblot
- Vehicle
- DMSO comparator shown; final concentration not specified
- Reported limits
- Final DMSO concentration is not specified. Exact percentage effects are withheld; see private review.
Methods and source locations
Compound reported in the paper: NSC 405020; Compound label in the paper: NSC405020
Compound-level applicability; no claim that an Adooq lot was tested in this study.
Results: MMP14 is required for the invasively sprouting 3D growth of LEC primed melanoma cells (NSC405020 paragraph); Figure 4—figure supplement 2d–e; Key resources; Methods: Inhibitor treatments, Western blot, Statistical analysis
Combined Notch3 and cleaved NICD3 band intensity normalized to actin: Western blot and Image Lab densitometry; two independent experiments, mean ± SD in supplement panel e; untreated and DMSO ±LEC comparison lanes in panel d. — Figure 4—figure supplement 2d–e and caption; Methods: Western blot; Statistical analysis